APPOINTMENTS UPDATE

Dr. Jairam selected as the new Chairman of India’s Medica Group of Hospitals

INDIA — Dr. Nandakumar Jairam has been appointed as the new Chairman of Medica Group of Hospitals, taking over from Founder and Former Chairman Dr. Alok Roy.

Bhavana Agrawal to takeover CFO role at AstraZeneca India on October 1

INDIA — AstraZeneca India has appointed Bhavana Agrawal as its new Chief Finance Officer (CFO) following the departure of Rajesh Marwaha.

Agrawal's appointment comes as the company prepares to establish new Centers of Excellence for asthma care in India. AstraZeneca has also introduced its rare disease drug Selumetinib in India after receiving regulatory approval, marking its entry into rare disease therapy in the country.

Agrawal will oversee the financial strategy and operations, planning and analysis, and investor relations in the Indian subcontinent. She brings extensive experience in finance functions in the healthcare and pharmaceutical industry, particularly in maximizing revenue, margin, and cash.

Agrawal will take over the CFO role from Marwaha, who played a significant role in building strategic frameworks for the company in India and improving access to healthcare. Marwaha plans to retire at the end of September 2023. AstraZeneca India expressed confidence in Agrawal's ability to accelerate growth and deliver life-changing medicines to patients through innovative science.

Medica Group of Hospitals is a major healthcare chain in Eastern India and has built and managed multiple multispecialty and super specialty healthcare facilities in the region. Dr. Jairam, with over 35 years of experience in the healthcare industry, will lead the strategic growth strategies of the group. He is an alumnus of Bangalore Medical College and has held various positions at Columbia Asia Hospitals in India, including Chairman and CEO.

Ken Washington takes the helm as Medtronic’s Chief Technology and Innovation Officer

IRELAND — Medtronic, a global leader in medical technology, has appointed Ken Washington as its Chief Technology and Innovation Officer.

Dr. Washington will be responsible for expanding the use of technology platforms across Medtronic's portfolio, focusing on areas such as robotics, sensors, implantables, and AI. With his background in technology leadership roles at Amazon and Ford Motor Company, Dr. Washington brings expertise to drive Medtronic's technological advancements and enhance its competitive advantage.

Dr. Jairam has been associated with organizations such as the NABH, FICCI, NATHEALTH, and GAPIO, and has been actively involved in setting quality benchmarks and promoting healthcare services. The leadership change was welcomed by Mr. R Udayan Lahiry, Co-founder & Director of Medica Synergie Private Limited, who expressed confidence in Dr. Jairam's ability to add value to the organization and continue its growth trajectory.

Under Dr. Jairam's leadership, Medica Group of Hospitals aims to expand its medical capabilities in Kolkata and other major cities in Bengal.

Dr. Washington's previous achievements include leading technology strategies at Ford Motor Company and holding advanced degrees in nuclear engineering. His appointment signifies Medtronic's dedication to advancing healthcare technology and driving growth through innovation.

This announcement follows Medtronic’s recent acquisition of South Korean wearable insulin patch maker, EOFlow, for a total consideration of KRW 971 billion (US$739 million). Furthermore, the company reported fourth-quarter sales of US$8.5 billion, reflecting a 5.6% increase compared to the same period last year.

DP World’s Aviv Clinics Dubai hires Craig Cook as its new CEO

UAE — Craig Cook, former Executive Director for International Operations at Cleveland Clinic, has been appointed as the new Chief Executive Officer (CEO) of Aviv Clinics Dubai.

The executive appointment comes as Aviv Clinics Dubai enters its third year in the United Arab Emirates (UAE), marking an exciting new chapter for the clinic.

Aviv Clinics Dubai, a subsidiary of DP World, offers cutting-edge assessments, treatments, and performance improvements for cognitive and physical health. It combines proprietary Hyperbaric Oxygen Therapy (HBOT), a patented cognitive and physical training

Chris Boerner appointed as CEO of Bristol Myers Squibb, succeeding Giovanni Caforio

USA — Bristol Myers Squibb (BMS) has announced that CEO Giovanni Caforio will step down in November, with Christopher Boerner, the company's Chief Commercialization Officer, taking over as CEO.

Boerner has been with BMS since 2015 and has held leadership positions in companies like Seattle Genetics and Roche's Genentech. Under Caforio's leadership, BMS experienced significant growth, tripling its revenue primarily through the acquisition of Celgene and launching 12 new medicines. However, BMS now faces challenges as the patents for its blockbuster drugs Eliquis and Opdivo are set to expire, and Revlimid is already facing generic competition.

Rui Morais to take over CEO role at Dis-Chem

SOUTH AFRICA — Effective from July 1, 2023, Rui Morais, the current Chief Financial Officer (CFO) of DisChem, will assume the role of Chief Executive Officer (CEO), following Ivan Saltzman's decision to step down after his remarkable 45-year tenure as cofounder and CEO of the company.

Morais, who has been with DisChem since 2010 and has played a pivotal role as CFO and a member of the executive leadership team, will now lead the company into its next phase of growth and development. His extensive experience and deep involvement in shaping the group's strategy over the past 11 years position him well for this new leadership role.

program, and personalized nutritional coaching optimized using advanced data analytics tools.

In his role as CEO, Craig Cook will be responsible for steering the growth and business development of Aviv Clinics. With over 30 years of international leadership experience in healthcare and hospitality, Cook brings a wealth of expertise to the position. He has previously held executive positions in healthcare and hospitality organizations across the Middle East, Asia Pacific, the Caribbean, and the United States.

These drugs accounted for a significant portion of BMS' sales. Nevertheless, BMS has a robust drug pipeline, including Sotyktu and Camzyos, which are expected to generate substantial revenue by 2030.

Adam Lenkowsky will assume Boerner's previous role as Chief Commercial Officer. Caforio became CEO in 2015 and oversaw the development of blockbuster drugs like Eliquis and Opdivo, as well as significant acquisitions.

BMS joins other large biopharmaceutical companies, such as Roche, Bayer, Biogen, Seagen, Astellas, Teva, and Viatris, in recent CEO changes.

As the incoming CEO, Morais will focus on steering the company's strategic objectives and ensuring its continued success. His appointment is part of a carefully planned leadership succession, reflecting the company's commitment to maintaining strong leadership and driving its strategic ambitions forward.

Ivan Saltzman, co-founder and outgoing CEO, will remain actively involved in the company as an executive director on the board. The leadership transition has been met with confidence by Larry Nestadt, Dis-Chem's chairman, who commended Saltzman's transformative leadership and expressed assurance in the carefully selected successor.